BRIEF-Sol Gel Technologies Ltd Phase 3 Trial Of Sgt-610 For Gorlin Syndrome Is Ongoing,Top-Line Results Expected Q4 2026
Reuters
Nov 20
BRIEF-Sol Gel Technologies Ltd Phase 3 Trial Of Sgt-610 For Gorlin Syndrome Is Ongoing,Top-Line Results Expected Q4 2026
Sol Gel Technologies Ltd SLGL.O:
SOL GEL TECHNOLOGIES LTD: PHASE 3 TRIAL OF SGT-610 FOR GORLIN SYNDROME IS ONGOING,TOP-LINE RESULTS EXPECTED Q4 2026
SOL GEL TECHNOLOGIES LTD: EXPECTS ITS CASH RESOURCES TO FUND CASH REQUIREMENTS INTO Q1 OF 2027
Source text: ID:nGNX1Y3Wwl
Further company coverage: SLGL.O
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.